158 related articles for article (PubMed ID: 35667975)
1. Changes in airway bacterial communities occur soon after initiation of antibiotic treatment of pulmonary exacerbations in cystic fibrosis.
Carmody LA; Kalikin LM; VanDevanter DR; Li G; Opron K; Simon RH; Caverly LJ; LiPuma JJ
J Cyst Fibros; 2022 Sep; 21(5):766-768. PubMed ID: 35667975
[TBL] [Abstract][Full Text] [Related]
2. Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability.
Caverly LJ; Lu J; Carmody LA; Kalikin LM; Shedden K; Opron K; Azar M; Cahalan S; Foster B; VanDevanter DR; Simon RH; LiPuma JJ
Ann Am Thorac Soc; 2019 Dec; 16(12):1534-1542. PubMed ID: 31415187
[No Abstract] [Full Text] [Related]
3. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
[TBL] [Abstract][Full Text] [Related]
4. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations.
Fodor AA; Klem ER; Gilpin DF; Elborn JS; Boucher RC; Tunney MM; Wolfgang MC
PLoS One; 2012; 7(9):e45001. PubMed ID: 23049765
[TBL] [Abstract][Full Text] [Related]
5. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
[TBL] [Abstract][Full Text] [Related]
6. The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation.
Caverly LJ; VanDevanter DR
J Pediatric Infect Dis Soc; 2022 Sep; 11(Supplement_2):S40-S45. PubMed ID: 36069900
[TBL] [Abstract][Full Text] [Related]
7. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
8. Decade-long bacterial community dynamics in cystic fibrosis airways.
Zhao J; Schloss PD; Kalikin LM; Carmody LA; Foster BK; Petrosino JF; Cavalcoli JD; VanDevanter DR; Murray S; Li JZ; Young VB; LiPuma JJ
Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5809-14. PubMed ID: 22451929
[TBL] [Abstract][Full Text] [Related]
9. Polymicrobial infections and antibiotic treatment patterns for cystic fibrosis pulmonary exacerbations.
Faino AV; Hoffman LR; Gibson RL; Kronman MP; Nichols DP; Rosenfeld M; Cogen JD
J Cyst Fibros; 2023 Jul; 22(4):630-635. PubMed ID: 36849332
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis.
Skolnik K; Nguyen A; Somayaji R; Thornton CS; Waddell B; Surette MG; Rabin HR; Parkins MD
BMC Pulm Med; 2015 Dec; 15():161. PubMed ID: 26651825
[TBL] [Abstract][Full Text] [Related]
11. Data Mining of Lung Microbiota in Cystic Fibrosis Patients.
Li J; Hao C; Ren L; Xiao Y; Wang J; Qin X
PLoS One; 2016; 11(10):e0164510. PubMed ID: 27741283
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.
Zemanick ET; Wagner BD; Harris JK; Wagener JS; Accurso FJ; Sagel SD
Pediatr Pulmonol; 2010 Jun; 45(6):569-77. PubMed ID: 20503282
[TBL] [Abstract][Full Text] [Related]
13. Pyrosequencing reveals transient cystic fibrosis lung microbiome changes with intravenous antibiotics.
Smith DJ; Badrick AC; Zakrzewski M; Krause L; Bell SC; Anderson GJ; Reid DW
Eur Respir J; 2014 Oct; 44(4):922-30. PubMed ID: 25034564
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
[No Abstract] [Full Text] [Related]
15. The metabolic footprint of the airway bacterial community in cystic fibrosis.
Narayanamurthy V; Sweetnam JM; Denner DR; Chen LW; Naureckas ET; Laxman B; White SR
Microbiome; 2017 Jun; 5(1):67. PubMed ID: 28666467
[TBL] [Abstract][Full Text] [Related]
16. Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention.
Cuthbertson L; Rogers GB; Walker AW; Oliver A; Green LE; Daniels TW; Carroll MP; Parkhill J; Bruce KD; van der Gast CJ
ISME J; 2016 May; 10(5):1081-91. PubMed ID: 26555248
[TBL] [Abstract][Full Text] [Related]
17. Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period.
Stokell JR; Gharaibeh RZ; Hamp TJ; Zapata MJ; Fodor AA; Steck TR
J Clin Microbiol; 2015 Jan; 53(1):237-47. PubMed ID: 25392361
[TBL] [Abstract][Full Text] [Related]
18. Cystic fibrosis lung microbiome: opportunities to reconsider management of airway infection.
Caverly LJ; Zhao J; LiPuma JJ
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40():S31-8. PubMed ID: 26335953
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.
Hoppe JE; Wagner BD; Accurso FJ; Zemanick ET; Sagel SD
J Cyst Fibros; 2018 Nov; 17(6):760-768. PubMed ID: 29921503
[TBL] [Abstract][Full Text] [Related]
20. Antibiotics and outcomes of CF pulmonary exacerbations in children infected with MRSA and Pseudomonas aeruginosa.
Cogen JD; Hall M; Faino AV; Ambroggio L; Blaschke AJ; Brogan TV; Cotter JM; Gibson RL; Grijalva CG; Hersh AL; Lipsett SC; Shah SS; Shapiro DJ; Neuman MI; Gerber JS
J Cyst Fibros; 2023 Mar; 22(2):313-319. PubMed ID: 35945130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
